Matthew Bin Han Ong
Matthew Bin Han Ong

Associate Editor

Matthew Ong is associate editor of The Cancer Letter. He joined the publication in 2012.

Matt’s reporting on the politics and business of cancer research and drug development have led to Congressional investigations, triggered action by FDA, CDC, FBI, and GAO, and helped change policy and standards of care.

His work has been recognized by the National Press Club, Society of Professional Journalists, Association of Health Care Journalists, The Poynter Institute, Society of American Business Editors and Writers, National Institute for Health Care Management Foundation, American Society of Business Publication Editors, American Association of University Professors, the Washington Media Institute, and Washington, DC Professional Chapter of the Society of Professional Journalists.

His stories have been picked up and cited in The Washington Post, The Wall Street Journal, The New York Review of Books, ABC News, CBS affiliates, The Boston Globe, Science, Nature, Inside Higher Ed, The Houston Chronicle, The Philadelphia Inquirer, The Journal of the American Medical Association, The British Medical Journal, The American Journal of Managed Care, and by the President’s Cancer Panel, CEO Roundtable on Cancer, CEO Cancer Life Sciences Consortium, and the American Association for Cancer Research. He has been interviewed on public radio programs, including NPR.

Matt is one of five journalists selected for the 2021 class of the Health Care Performance Fellowship, the Association of Health Care Journalists's most prestigious fellowship, which is supported by The Commonwealth Fund. In 2020, he was selected from over 130 journalists by the Poynter Institute and The Washington Post to join the 2020-21 Leadership Academy for Diversity in Digital Media. He was also chosen as a fellow for AHCJ’s inaugural 2016 class of the National Cancer Reporting Fellowships at the National Cancer Institute, and the 2017 Comparative Effectiveness Research Fellowship at the Patient-Centered Outcomes Research Institute. He serves as a guest speaker for AHCJ’s fellowships and annual Health Journalism conferences.

Matt graduated from Marquette University in 2012, majoring in journalism, psychology, as well as women’s and gender studies. His CV is available on

Latest Stories

Health Equity
FDA watchers and clinical trialists in oncology may want to pay close attention to the agency’s latest plans to increase representation of traditionally marginalized populations in drug development.
Health Equity
There’s a cultural perception in drug development that enrolling a diverse, heterogeneous patient cohort can be “risky” for detecting drug effects—a perception that needs to go away, said Lola Fashoyin-Aje, associate director of the Science & Policy Program to Address Disparities at the FDA’s Oncology Center of Excellence and a deputy division director in the agency’s Office of Oncologic Diseases.
Health Equity
Drug manufacturers and researchers have a moral obligation to design clinical trials that adequately represent the target population for the investigational agent—and these medical products need to be safe and effective for everyone, leading clinical trial experts in oncology say.
Health Equity
The Association of American Cancer Institutes is designing two programs to address systemic underrepresentation of racial and ethnic minority physicians and scientists in leadership positions in oncology.
Conversation with The Cancer Letter
The Cancer Prevention and Research Institute of Texas will focus on finding solutions for health disparities among patients with cancer, Michelle Le Beau, the institute’s new chief scientific officer, said to The Cancer Letter.
Francis Collins will step down as director of NIH by the end of 2021, closing out a chapter in his career as the longest-serving presidentially appointed NIH director.